Innoviva Stock Price and Value Analysis

Should you buy Innoviva stock? (NasdaqGS:INVA). Let's see how it does in our automated value investing analysis system.

INVA Free Cash Flow Trend

Free Cash Flow trendline for INVA — Free Cash Flow trendline for Innoviva

Hmm, we can't give any reliable projection for Innoviva's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Advantages	Disadvantages	Neutral
This company has amazingly consistent growth!	This company is not making money. This company is less known than others. This stock looks overpriced.	This company pays no dividend.

Inside the INVA Numbers

	INVA Price (Innoviva stock price per share)	$11.48
	PE Ratio versus Sector	83% lower than other Healthcare stocks
	PE Ratio versus Industry	94% lower than other Biotechnology stocks

Is Innoviva Stock on Sale?

Based on our analysis, we believe that you should not buy Innoviva right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy INVA Stock?

Does Innoviva have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.